<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585559</url>
  </required_header>
  <id_info>
    <org_study_id>NIH P50 GM015431</org_study_id>
    <secondary_id>VUMCIRB060556</secondary_id>
    <secondary_id>P50GM015431</secondary_id>
    <nct_id>NCT00585559</nct_id>
  </id_info>
  <brief_title>Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm</brief_title>
  <official_title>Inhibition of Lipid Peroxidation and Cerebral Vasospasm by an Acetaminophen-Based Regimen in Patients With Aneurysmal Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether acetaminophen (APAP), N-acetylcysteine&#xD;
      (NAC), and APAP in combination with NAC will inhibit lipid peroxidation in aneurysmal&#xD;
      subarachnoid hemorrhage (aSAH), utilizing F2-IsoPs as biomarkers for lipid peroxidation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aneurysmal subarachnoid hemorrhage (aSAH) is an often devastating form of stroke with high&#xD;
      morbidity and mortality despite advances in surgical management. Approximately 30,000&#xD;
      patients annually suffer aSAH in the U.S. For patients who survive the initial subarachnoid&#xD;
      hemorrhage, delayed cerebral vasospasm occurring from days 4-14 is the greatest cause of&#xD;
      neurological disability and death. A growing body of evidence incriminates&#xD;
      hemoprotein-catalyzed lipid peroxidation as the mediator of the vasospasm.&#xD;
&#xD;
      Hemoglobin released from lysed red cells in the subarachnoid space becomes oxidized, in which&#xD;
      state it acts as a pseudoperoxidase and generates the protein radicals that induce lipid&#xD;
      peroxidation. F2-isoprostanes formed by this lipid peroxidation are highly potent&#xD;
      constrictors of cerebral arterioles. We have demonstrated a more than 5 fold mean increase in&#xD;
      F2-isoprostanes in the cerebrospinal fluid of patients with aSAH; this increase is maximal at&#xD;
      the time of delayed vasospasm, and the level of increase is a function of the severity of the&#xD;
      aSAH. We hypothesize that such vasoconstrictors are major contributors to the vasospasm&#xD;
      produced by the hemoproteins, hemoglobin and myoglobin, in diseases in which they are&#xD;
      released from their cellular confines.&#xD;
&#xD;
      We have discovered that acetaminophen (APAP) is a potent inhibitor of hemoprotein-catalyzed&#xD;
      lipid peroxidation with an IC50 for hemoglobin of 15 uM, which is in the range of plasma&#xD;
      levels resulting from therapeutic doses of the drug in humans. Acetaminophen acts by reducing&#xD;
      the ferryl-oxo radical form of the heme, and thereby prevents formation of the hemoprotein&#xD;
      radical that initiates lipid peroxidation. To assess proof of concept in vivo, we determined&#xD;
      the effect of acetaminophen in a rat model of rhabdomyolysis in which renal failure results&#xD;
      from intense vasospasm. Acetaminophen blocked lipid peroxidation in this model, and prevented&#xD;
      the renal failure with a dose that produced plasma levels in the therapeutic range for&#xD;
      humans.&#xD;
&#xD;
      We also have demonstrated that N-acetylcysteine (NAC) will inhibit hemoprotein-catalyzed&#xD;
      lipid peroxidation. Moreover, NAC administration increases the levels of glutathione in vivo,&#xD;
      and glutathione is a co-substrate for the glutathione peroxidases that can reduce the levels&#xD;
      of peroxides in the environment of the aSAH . This is important as acetaminophen is most&#xD;
      potent in inhibiting hemoprotein-catalyzed lipid peroxidation when peroxide concentrations&#xD;
      are low. This concerted evidence is the basis for a hypothesis that NAC will augment the&#xD;
      efficacy of acetaminophen as an inhibitor of hemoprotein-catalyzed lipid peroxidation in&#xD;
      aSAH.&#xD;
&#xD;
      These finding provide the rationale for a pilot study seeking proof of the concept that&#xD;
      acetaminophen-based regimens can inhibit lipid peroxidation in patients with subarachnoid&#xD;
      hemorrhage. Lipid peroxidation will be determined by analysis of F2-isoprostanes in&#xD;
      cerebrospinal fluid. If such inhibition is seen, that then would provide a basis for a larger&#xD;
      multi-center investigation to assess the effect on clinical endpoints.&#xD;
&#xD;
      This pilot study will determine whether APAP, NAC, and APAP in combination with NAC will&#xD;
      inhibit lipid peroxidation in aneurysmal subarachnoid hemorrhage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The study is to determine whether APAP, NAC, and APAP with NAC will inhibit lipid peroxidation in (aSAH), utilizing F2-IsoPs as biomarkers for lipid peroxidation. The effect on the F2-IsoPs will be the primary study endpoint.</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether APAP and APAP with NAC will inhibit vasospasm and brain ischemia in aSAH, as assessed by CTA w/perfusion imaging or MRI and diffusion weighted images.</measure>
    <time_frame>8 +/- days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <condition>Cerebral Vasospasm</condition>
  <arm_group>
    <arm_group_label>Placebos for acetaminophen and N-acetylcysteine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebos for acetaminophen and N-acetylcysteine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen and N-acetylcysteine placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine and acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen 1 Gram and N-acetylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen 1.5 Gram and N-acetylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos for acetaminophen and N-acetylcysteine</intervention_name>
    <description>Placebos for acetaminophen and N-acetylcysteine</description>
    <arm_group_label>Placebos for acetaminophen and N-acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APAP 1 gm every 6 hours and N-acetylcysteine placebo</intervention_name>
    <description>Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo</description>
    <arm_group_label>Acetaminophen and N-acetylcysteine placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NAC IV infusion at 0.5 gm hourly and APAP placebo</intervention_name>
    <description>N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo</description>
    <arm_group_label>N-acetylcysteine and acetaminophen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly</intervention_name>
    <description>Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly</description>
    <arm_group_label>Acetaminophen 1 Gram and N-acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly</intervention_name>
    <description>Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly</description>
    <arm_group_label>Acetaminophen 1.5 Gram and N-acetylcysteine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages â‰¥ 20&#xD;
&#xD;
          -  Fisher Grade III or III + IV SAH based upon admitting CT scan&#xD;
&#xD;
          -  Aneurysm secured by either clipping or coiling within 72 hours of SAH&#xD;
&#xD;
          -  Intracranial aneurysm confirmed by angiography or CTA&#xD;
&#xD;
          -  Presence of ventriculostomy for external ventricular drainage (EVD) prior to&#xD;
             randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consent unobtainable&#xD;
&#xD;
          -  Enrollment in another interventional study&#xD;
&#xD;
          -  Patient is pregnant or lactating&#xD;
&#xD;
          -  Known co-morbidities that could affect outcome of this study&#xD;
&#xD;
          -  Contraindication to CTA&#xD;
&#xD;
          -  Serum creatinine &gt; 1.4&#xD;
&#xD;
          -  Documented allergy to iodinated contrast that cannot be adequately treated with&#xD;
             premedication&#xD;
&#xD;
          -  Documented allergy and/or intolerance to ApAP&#xD;
&#xD;
          -  Baseline liver disease&#xD;
&#xD;
          -  History of recent alcohol abuse with documented ALT or AST above normal laboratory&#xD;
             values&#xD;
&#xD;
          -  Documented history of both malnutrition and decreased serum albumin below normal lab&#xD;
             values&#xD;
&#xD;
          -  Documented abnormal platelet count below normal lab values&#xD;
&#xD;
          -  Documented abnormal PT or PTT above normal lab values&#xD;
&#xD;
          -  History or evidence of active asthma&#xD;
&#xD;
          -  Documented allergy and/or intolerance to N-acetylcysteine&#xD;
&#xD;
          -  Currently taking phenytoin, carbamazepine, or phenobarbital&#xD;
&#xD;
          -  Currently taking isoniazid (INH, Lanzid, Nydrazid)&#xD;
&#xD;
          -  Severe life-threatening complications resulting from standard aneurysm treatments that&#xD;
             will likely prevent completion of the study&#xD;
&#xD;
          -  Patient unsuitable for the study, in the opinion of the investigator(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Fusco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew F Fusco, MD</last_name>
    <phone>615-322-7417</phone>
    <email>matthew.r.fusco@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Fusco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Matthew Fusco</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Lipid</keyword>
  <keyword>Peroxidation</keyword>
  <keyword>N-Acetylcysteine</keyword>
  <keyword>Acetaminophen</keyword>
  <keyword>Vasospasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Vasospasm, Intracranial</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

